Top in GI: New H. Pylori treatments, advances in colonoscopy
Click Here to Manage Email Alerts
The FDA has approved two treatments for Helicobacter pylori infection in adults. Both regimens contain vonoprazan, a potassium-competitive acid blocker. The announcement was the top story in gastroenterology last week.
The second top story highlights recent developments in the management of colorectal cancer, including updated U.S. Preventive Services Task Force recommendations and advancements in the technology behind colonoscopy scans.
Read these and more top stories in gastroenterology below:
FDA approves two vonoprazan treatment regimens for H. pylori infection
Phathom Pharmaceuticals Inc. has announced FDA approval for its Voquezna Triple Pak (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and Voquezna Dual Pak (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. Read more.
Emerging technologies could spark ‘revolutionary’ advances in colonoscopy
Colorectal cancer is the third leading cause of cancer-related deaths in the United States, for both men and women, and across the entire population represents the second most common cause of cancer deaths and diagnoses. Read more.
CDC: Adenovirus should be considered in diagnosis of acute hepatitis in children
Several cases of acute, severe hepatitis in children in Alabama provided additional evidence in support of a possible link between this illness and adenovirus, according to a report published in Morbidity and Mortality Weekly Report. Read more.
PPI use should be limited to appropriate indications, lowest effective dose in cirrhosis
Although proton pump inhibitors were linked with an increased risk for infection and decompensation in patients with cirrhosis, they may still be of benefit in those with prior gastrointestinal bleeding, according to published data. Read more.
CDC: Investigation ongoing, need time to evaluate evidence for acute hepatitis in children
The CDC reported during a media telebriefing that it is investigating cases of acute hepatitis of unknown etiology among children in the United States but warns it will take time to evaluate evidence. Read more.